Dafinchi
Bio-Rad Q1 2026 Margins Expected to Dip Due to Middle East Conflict
This analysis explores how the ongoing Middle East conflict has already affected Bio-Rad's gross margins in Q1 2026 and forecasts continued impacts throughout the year.
Read post
Detailed company information
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 04, 2026
Earnings Transcript for 2026 - Q1Released: May 01, 2026
Earnings Transcript for 2025 - Q4Released: Feb 12, 2026
Earnings Transcript for 2025 - Q3Released: Oct 29, 2025
Earnings Transcript for 2025 - Q2Released: Jul 31, 2025
Earnings Transcript for 2025 - Q1Released: May 01, 2025
Earnings Transcript for 2024 - Q4Released: Feb 13, 2025
Earnings Transcript for 2024 - Q3Released: Oct 30, 2024
Earnings Transcript for 2024 - Q2Released: Aug 01, 2024
Earnings Transcript for 2024 - Q1Released: May 07, 2024
Earnings Transcript for 2023 - Q4Released: Feb 15, 2024
Earnings Transcript for 2023 - Q3Released: Oct 26, 2023
Earnings Transcript for 2023 - Q2Released: Aug 03, 2023
Earnings Transcript for 2023 - Q1Released: May 04, 2023
Earnings Transcript for 2022 - Q4Released: Feb 16, 2023
Earnings Transcript for 2022 - Q3Released: Oct 27, 2022
Earnings Transcript for 2022 - Q2Released: Jul 28, 2022
Earnings Transcript for 2022 - Q1Released: Apr 28, 2022
Earnings Transcript for 2021 - Q4Released: Feb 10, 2022
Earnings Transcript for 2021 - Q3Released: Oct 28, 2021
Earnings Transcript for 2021 - Q2Released: Jul 29, 2021
Earnings Transcript for 2021 - Q1Released: Apr 30, 2021
Earnings Transcript for 2020 - Q4Released: Feb 11, 2021
Earnings Transcript for 2020 - Q3Released: Oct 30, 2020
ANIK Anika Therapeutics, Inc.
This analysis explores how the ongoing Middle East conflict has already affected Bio-Rad's gross margins in Q1 2026 and forecasts continued impacts throughout the year.
Read post